HC Wainwright Reaffirms Buy Rating for Chimerix (NASDAQ:CMRX)

Chimerix (NASDAQ:CMRX)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $11.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 128.26% from the stock’s current price.

Separately, Wedbush reissued an “outperform” rating and issued a $6.00 target price on shares of Chimerix in a report on Tuesday, December 10th.

Chimerix Stock Up 10.0 %

NASDAQ:CMRX traded up $0.44 during mid-day trading on Tuesday, hitting $4.82. 4,342,922 shares of the company traded hands, compared to its average volume of 1,546,786. The stock’s fifty day moving average price is $3.60 and its 200-day moving average price is $1.85. The firm has a market cap of $433.42 million, a price-to-earnings ratio of -5.13 and a beta of 0.35. Chimerix has a one year low of $0.75 and a one year high of $5.15.

Insider Buying and Selling at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the sale, the chief executive officer now owns 609,603 shares in the company, valued at $2,755,405.56. This trade represents a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 20,760 shares of company stock valued at $91,175 over the last ninety days. 13.10% of the stock is currently owned by company insiders.

Institutional Trading of Chimerix

Several hedge funds have recently bought and sold shares of the stock. Stoneridge Investment Partners LLC lifted its holdings in shares of Chimerix by 22.5% in the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 8,134 shares during the last quarter. Bender Robert & Associates purchased a new stake in Chimerix during the fourth quarter valued at approximately $37,000. Susquehanna Fundamental Investments LLC purchased a new stake in Chimerix during the fourth quarter valued at approximately $59,000. Jane Street Group LLC bought a new stake in shares of Chimerix in the 4th quarter valued at approximately $62,000. Finally, Diadema Partners LP purchased a new position in shares of Chimerix in the 4th quarter worth approximately $101,000. Hedge funds and other institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.